NeoART Trial: Safety and Activity of T-DXd plus 5-FU/FA for HER2-Positive Gastric Cancer

Six patients were recruited for the safety run-in cohort of the phase Ib/II NeoART trial. The dataset contains supplementary material reporting on the safety, feasibility, and preliminary antitumor activity of a neoadjuvant regimen combining trastuzumab deruxtecan with 5-fluorouracil and folinic acid for HER2-positive, resectable esophagogastric adenocarcinoma. The material was authored by figshare admin karger and last updated on June 1, 2026.

Use Cases

• Reviewing safety and adverse event profiles for a novel neoadjuvant combination therapy based on the reported grades 1-3 diarrhea, mucositis, and nausea.
• Assessing preliminary efficacy signals based on reported outcomes like histopathological complete remission (pCR) and R0 resection rates.
• Evaluating trial feasibility and patient management based on details of surgical outcomes and postoperative complications.
• Informing the design of subsequent clinical trials based on the safety run-in results from this phase Ib/II study.

Strengths

• Dataset is associated with a specific, named clinical trial (phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART trial).
• Provides detailed safety and preliminary activity results for a cohort of six patients, including specific adverse event types and surgical outcomes.
• Released under a permissive CC-BY-4.0 license, facilitating reuse.

Limitations

• Row count and column-level documentation are absent; data structure must be inferred after download.
• The dataset is very small at 36.8 KB, representing supplementary material for a safety run-in cohort of only six patients.
• The primary file format is DOCX, which may require conversion for computational analysis.

Provenance

Source

figshare

Collection Method

Clinical trial results from the safety run-in cohort of the NeoART trial.

Freshness

Last updated 2026-06-01 07:15:04